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Fluorescent ligand technologies have proved to be powerful tools to improve our un-
derstanding of ligand- receptor interactions. Here we have characterized a small fo-
cused library of nine fluorescent ligands based on the highly selective β2- adrenoceptor 
(β2AR)	antagonist	 ICI	118,551.	The	majority	of	fluorescent	 ICI	118,551	analogs	had	
good affinity for the β2AR	(pKD	>7.0)	with	good	selectivity	over	the	β1AR	(pKD	<6.0).	
The most potent and selective ligands being 8c	 (ICI	118,551-	Gly-	Ala-	BODIPY-	FL-	X;	
β2AR	 pKD	 7.48),	 9c	 (ICI	 118,551-	βAla-	βAla-	BODIPY-	FL-	X;	 β2AR	 pKD	 7.48),	
12a	 (ICI	 118,551-	PEG-	BODIPY-	X-	630/650;	 β2AR	 pKD	 7.56),	 and	 12b (ICI 
118,551-	PEG-	BODIPY-	FL;	β2AR	pKD	 7.42).	9a	 (ICI	118,551-	βAla-	βAla-	BODIPY-	X-	63
0/650)	had	the	highest	affinity	at	recombinant	β2ARs	(pKD	7.57),	but	also	exhibited	
significant binding affinity to the β1AR	(pKD	6.69).	Nevertheless,	among	the	red	fluo-
rescent	 ligands,	9a	 had	 the	best	 imaging	 characteristics	 in	 recombinant	HEK293	T	
cells	and	 labeling	was	mostly	confined	to	the	cell	 surface.	 In	contrast,	12a showed 
the highest propensity to label intracellular β2ARs	in	HEK293	T	cell	expressing	exog-
enous β2ARs.	This	suggests	that	a	combination	of	the	polyethylene	glycol	(PEG)	linker	
and	the	BODIPY-	X-	630/650	makes	this	ICI	118,551	derivative	particularly	susceptible	
to crossing the cell membrane to access the intracellular β2ARs.	We	have	also	used	
these	 ligands	 in	 combination	with	CRISPR/Cas9	genome-	edited	HEK293	T	cells	 to	
undertake	for	the	first	time	real-	time	ligand	binding	to	native	HEK293	T	β2ARs	at	low	
native	receptor	expression	levels.	These	studies	provided	quantitative	data	on	ligand-	
binding characteristics but also allowed real- time visualization of the ligand- binding 
interactions	in	genome-	edited	cells	using	NanoBRET	luminescence	imaging.
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1  |  INTRODUC TION
Beta-	adrenoceptors	(βARs)	are	Class	A	G	protein-	coupled	receptors	
(GPCRs)	which	 have	 been	 successfully	 targeted	 for	 the	 treatment	
of cardiovascular and respiratory disorders.1,2 There are three re-
ceptor	subtypes,	β1AR,	β2AR, and β3AR,	which	display	tissue-	specific	
localization and functionality.3- 5	All	three	subtypes	are	found	in	the	
heart,	with	the	β1AR	being	the	most	abundant	and	is	able	to	regulate	
heart rate and contractile force.6 β2ARs	can	couple	to	both	Gαs and 
Gαi heterotrimeric G proteins.
7- 9 They are found within the smooth 
muscle of the airways and can be targeted to relieve symptoms of 
respiratory	disorders,	such	as	asthma	and	chronic	obstructive	pul-
monary disease.2,9 The β3AR	has	 limited	expression,	chiefly	 in	adi-
pose	tissue	and	the	bladder,	but	can	also	be	found	at	low	expression	
levels in the heart.10- 12
The β2AR	is	a	commonly	used	model	for	Class	A	GPCRs	within	
research. This has been facilitated by the myriad of tools with which 
to	study	its	role	and	function,	including	numerous	published	crystal	
structures showing the receptor in an inactive state bound to the 
negative	allosteric	nanobody	60,13	as	well	as	the	agonist,14- 16 inverse 
agonist,17 and G protein- bound states.15	Traditionally,	ligand-	binding	
parameters have been determined using radiolabeled ligands as the 
pharmacological	probe.	However,	these	approaches	are	not	readily	
applicable to the study of receptor properties in living cells and in 
real time.
Recent advances in fluorescent ligand design have allowed 




resonance energy transfer.18-	24 The composition of the fluorescent 
ligand	 (the	orthosteric	binding	moiety,	 linker	and	 fluorophore)	can	
exert	significant	effects	on	its	utility	as	a	probe,	including	modulat-
ing the selectivity profile of the probe and changing its photochem-
ical	properties,	which	affects	 its	use	for	confocal	microscopy.25 To 




Fusion of a luciferase to a receptor of interest has allowed a 
range of biological effects to be investigated using bioluminescence 
resonance	energy	transfer	(BRET).28 We have recently shown how 
fluorescent ligands can be used in combination with nanolucifer-




receptors interact and signal. To maintain the normal cellular con-
text,	 we	 have	 previously	 used	 CRISPR/Cas9-	mediated	 homology-	
directed repair to insert luminescent tags into the endogenous 
genome.30- 32	Here,	we	describe	novel	and	highly	selective	fluores-
cent ligands based on the β2AR	selective	antagonist	 ICI	118,551
33 
and linked to different fluorophores with a variety of linkers. We 
characterize these ligands in terms of βAR	 affinity	 and	 selectivity	
using	 a	 NanoBRET	 proximity-	based	 binding	 assay29	 and	 examine	
their imaging properties via confocal microscopy. We also use them 
to demonstrate fluorescent ligand binding to genome- edited β2ARs	
at	low	native	levels	of	receptor	expression	in	HEK293	T	cells.
2  |  MATERIAL S AND METHODS
2.1  |  Materials
FuGENE	 and	 furimazine	 were	 obtained	 from	 Promega.	 SNAP-	
Surface®,	Alexa	Fluor®	488	and	Alexa	Fluor	647	were	obtained	from	
New	England	Biolabs.	3H-	CGP12177	and	MicroScint	20	were	 from	
Perkin	 Elmer.	All	 other	 chemicals	were	 from	Sigma-	Aldrich.	Nunc™	
Lab-	Tek™	chambered	coverglass	(155361)	was	obtained	from	Thermo	
Fisher Scientific. 96- well white clear- bottomed plates and 35 mm 
Cellview	4-	quadrant	culture	dishes	were	from	Greiner	Bio-	One.
2.2  |  Chemistry
Chemicals	 and	 solvents	 of	 analytical	 and	HPLC	 grade	were	 pur-
chased from commercial suppliers and used without further 
purification.	 BODIPY-	630/650-	X-	SE,	 BODIPY-	FL-	X-	SE,	 and	
BODIPY-	FL-	SE	were	 purchased	 from	Molecular	 Probes	 (Thermo	
Fisher	Scientific).	All	 reactions	were	carried	out	at	ambient	 tem-
perature unless otherwise stated. Reactions were monitored 
by thin- layer chromatography on commercially available silica 
pre-	coated	 aluminum-	backed	 plates	 (Merck	 Kieselgel	 60	 F254).	
Visualization	was	under	UV	light	(254	nm	and	366	nm),	followed	by	
staining	with	ninhydrin	or	KMnO4 dips. Flash column chromatog-
raphy	was	performed	using	silica	gel	60,	230–	400	mesh	particle	
size	(Sigma-	Aldrich).	NMR	spectra	were	recorded	on	a	Bruker-	AV	
400. 1H spectra were recorded at 400.13 Hz and 13C	NMR	spectra	
at	101.62	Hz.	All	13C	NMR	are	1H broadband decoupled. Solvents 
used	 for	NMR	analysis	 (reference	peaks	 listed)	were	CDCl3 sup-
plied	 by	 Cambridge	 Isotope	 Laboratories	 Inc.,	 (δH	 =	 7.26	 ppm,	
δC	 =	 77.16)	 and	 CD3OD supplied by VWR (δH = 3.31 ppm and 
δC	=	49.00).	Chemical	 shifts	 (δ)	 are	 recorded	 in	parts	per	million	
(ppm)	 and	 coupling	 constants	 are	 recorded	 in	Hz.	 The	 following	












spectrometer	 using	 MS	 electrospray	 ionization	 operating	 in	
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positive	 ion	mode.	RP-	HPLC	was	performed	on	a	Waters	515	LC	








formic acid in CH3CN	 (method	B)).	Analytical	RP-	HPLC	was	per-
formed	using	a	YMC-	Pack	C8	column	 (150	mm	×4.6	mm	×5	μm)	




formic acid in CH3CN).
Full	experimental	detail	for	the	synthesis	of	fluorescent	ligands	
can be found in the Data S1.
2.3  |  Cell lines





transiently	 expressed	 in	HEK293	GloSensor	 cells	 (Promega)	 using	
FuGENE	 (Promega),	 according	 to	 the	 manufacturer's	 instructions.	
Briefly,	HEK293	GloSensor	 cells	 (120,	 000/well)	were	plated	on	 a	





Dr	 Karolina	 Gherbi	 (University	 of	 Nottingham).	 CRISPR/Cas9	 ge-
nome engineering of the N- terminal region of the β2AR	 genomic	
locus	in	HEK293	T	cells	to	incorporate	either	a	SNAP-	or	an	NLuc-	
tag was performed as described previously.32,35 Chinese Ovary 
Hamster	(CHO)	cell	lines	stably	expressing	either	the	β1AR	or	β2AR	
were	maintained	 in	DMEM/F12	 supplemented	with	 10%	FBS	 and	
2	mM	L-	glutamine	at	37°C	in	5%	CO2. The CHO cell lines were a gift 
from	Prof.	Jillian	Baker	(University	of	Nottingham).
2.4  |  NanoBRET binding assay
Saturation and competition binding assays were performed as 
previously described.29 Cells were seeded in 96- well white clear- 




in the presence or absence of 10 μM	propranolol	(saturation	binding	
assays)	or	 competing	 ligand	 in	 the	presence	of	10	nM	 fluorescent	
ligand	 (competition	binding	assays)	 in	HEPES-	buffered	saline	solu-
tion	(HBSS;	145	mM	NaCl,	5	mM	KCl,	1.3	mM	CaCl2,	1	mM	MgSO4,	
10	 mM	 HEPES,	 2	 mM	 sodium	 pyruvate,	 1.5	 mM	 NaHCO3,	 and	
10	mM	D-	glucose,	pH	7.45)	with	0.1%	bovine	serum	albumin	for	1	hr	
at	 37°C.	 The	 NanoLuc	 substrate,	 furimazine	 (Promega),	 was	 then	






the	 BODIPY-	FL	 and	 BODIPY-	X-	FL	 ligands	 were	 simultaneously	
measured.	BRET	ratios	were	calculated	by	dividing	the	longer	wave-
length	emission	by	the	460	nm	or	475	nm	emission,	respectively.
2.5  |  Radioligand binding
Competition binding assays were performed as previously de-
scribed36 using CHO- β1AR	 or	 CHO-	β2AR	 cell	 lines.	 Briefly,	 cells,	




serum- free medium. Non- specific binding was assessed by incubat-
ing	in	the	presence	of	10	µM	propranolol.	Cells	were	washed	twice	
in	PBS	before	addition	of	200	µL	MicroScint	20	(PerkinElmer),	then	
incubated in the dark overnight before being read on a TopCount 
Microplate	Scintillation	Counter	(Packard	Instrument,	CT).










Cells	 were	 imaged	 on	 a	 Zeiss	 LSM880	 with	 a	 Zeiss	 Axio	
Observer	Z1	 stand	 (Carl	Zeiss)	with	 a	40×	C-	apochromat	NA1.2	
water	 immersion	 objective.	 Excitation	 was	 via	 488	 nm	 Argon	
and	 633	 nm	 helium-	neon	 laser	 lines	with	 a	 488/561/633	multi-
beam	 splitter	 and	 emission	 collected	 using	 a	 493–	628	bandpass	
or	638–	737	bandpass.	The	pinhole	was	set	at	1	Airy	unit	for	the	
longer wavelength and laser power and gain and offset settings 
kept	constant	within	experiment	to	allow	comparison.	Cells	were	
imaged	live	at	24ºC	following	a	30	min	pre-	incubation	at	37ºC	in	
the	 presence	 of	 fluorescent	 ligand	 (100	 nM)	 following	 a	 30	min	
pre-	incubation	 at	 37ºC	 in	 the	 presence	 or	 absence	 of	 10	 μM	














oil	 immersion	 objective	 with	 a	 0.5x	 tube	 lens,	 following	 addi-
tion	of	 furimazine	 (5	µM)	 (Promega).	 Images	were	captured	by	a	
C9100-	23B	 IMAGE	EMX2	camera	 (Hamamatsu,	Japan)	with	gain	
set at 200 for all channels. Filtered bioluminescence was captured 
using	 a	 438/24	 nm	 band-	pass	 filter	 (5	 s	 –	 1	min	 exposure	 time	
dependent	on	expression	 level),	BRET	in	the	presence	of	9a was 
captured using a 650/50 nm band- pass filter and in the presence 
of 12c	using	a	509/22	nm	band-	pass	filter.	For	the	NLuc-	β2AR	sta-
ble	cell	line,	exposure	times	were	set	at	10	s	(12a,9a)	or	20	s	(9c)	
for filtered bioluminescence and 1 min (9a, 12a)	 or	20	 s	 (9c)	 for	
BRET,	 and	 for	 the	HEK293	 T	 cells	 expressing	NLuc-	β2AR	 under	
endogenous	promotion,	exposure	times	were	set	at	1	min	for	fil-
tered	bioluminescence	and	4	min	for	BRET.	Raw	intensity	values	
were	determined	 for	3–	5	 regions	of	 interest	per	experiment	per	
condition	and	the	BRET	ratio	was	calculated	by	dividing	the	raw	
intensity	 recorded	 from	 the	BRET	 capture	 by	 the	 filtered	 biolu-
minescence	capture.	Corrected	BRET	ratios	were	determined	by	
subtracting	 the	 BRET	 ratio	 determined	 from	 a	 control	 quadrant	
(HBSS	alone).	A	minimum	of	three	separate	experiments	were	per-
formed for each condition.
2.8  |  Data analysis
Data	 were	 analyzed	 using	 Prism	 7.4	 software	 (GraphPad,	 San	
Diego,	USA).	Saturation	NanoBRET	curves	were	fitted	simultane-





(nM),	m	is	the	slope	of	the	non-	specific	binding	component,	and	c is the 
y-	axis	intercept.
The affinities of ligands at the β2-	AR	were	calculated	from	com-
petition binding data with a one- site sigmoidal response curve given 
by	the	following	equation:
where	[A]	is	the	concentration	of	unlabeled	ligand,	n is the Hill coeffi-
cient,	and	IC50 	is	the	concentration	of	ligand	required	to	inhibit	50%	of	
fluorescent ligand. The IC50 values were then used to calculate the Ki 
values	using	the	Cheng-	Prusoff	equation:
where	[L]	is	the	concentration	of	fluorescent	ICI	118,551	ligand	in	nM,	




Bioluminescence	 and	 NanoBRET	 images	 were	 analyzed	 using	
ImageJ	 (http://rsb.info.nih.gov/ij;	 NIH,	 USA)	 and	 the	 Time	 Series	
Analyzer	 version	 3.0	 (https://imagej.nih.gov/ij/plugi	ns/time-	series.
html).37
2.9  |  Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked 
to corresponding entries in http://www.guide topha rmaco logy.
org,	 the	 common	portal	 for	 data	 from	 the	 IUPHAR/BPS	Guide	 to	
PHARMACOLOGY,38 and are permanently archived in the Concise 
Guide	to	PHARMACOLOGY	2019/20.39
3  |  RESULTS
3.1  |  Synthesis of ICI 118,551 fluorescent ligands
The highly β2AR-	selective	antagonist	 ICI	118,551	was	used	as	
the starting point for the development of selective β2AR	fluo-
rescent ligands. The crystal structure of the human β2AR	bound	
to	 this	 ligand	 has	 been	 previously	 solved	 (PDB	3NY840	 ;)	 and	
this aided identification of an appropriate attachment point on 
ICI	 118,551	 for	 a	 fluorophore	 via	 different	 linkers.	 In	 parallel	
to our own previous successes in designing and synthesizing 
fluorescent β-	adrenoceptor	 ligands,27,41 the crystal structure 
suggested	 the	 alkylated	 amine	 as	 an	 ideal	 tether-	point,	while	
ensuring retention of its basic pharmacophoric properties. We 
therefore generated a small focused library of nine ligands 
based on combinations of three linkers and three fluorophores 
(Figure	 1),	 since	 previous	 work	 had	 demonstrated	 that	 both	
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properties.25,42,43	 The	 linkers	 connecting	 the	 ICI	 118,551	 or-
thostere to the fluorophore consisted of a polyethylene gly-
col	 (PEG)	 chain	 (12a- c),	 a	 Gly-	Ala	 dipeptide	 linker	 (8a- c),	 or	
a β-	Ala-	β-	Ala	 (9a- c)	 linker	 (Figure	 1),	 and	 were	 chosen	 based	
on	earlier	experience	and	 the	 success	of	PEG	and	β-	Ala-	β-	Ala	
linkers in previous work with fluorescent propranolol deriva-
tives	[27,	41].	To	allow	spectral	choice	for	these	tools,	BODIPY-	
630/650-	X	 (red-	emitting),	 BODIPY-	FL	 (green-	emitting),	 or	
BODIPY-	FL-	X	(green-	emitting)	fluorophores	were	utilized.	The	
synthetic approach to the generation of these fluorescent li-
gands is detailed in Data S1 and Figure S1.
3.2  |  Pharmacological characterization of 
fluorescent ICI 118,551 analogs
Initial	 NanoBRET	 saturation	 binding	 experiments29 were per-
formed	 with	 all	 nine	 fluorescent	 ligands	 at	 the	 NLuc-	β2AR	 and	
NLuc-	β1AR	 receptors	 to	 determine	 their	 affinity	 (KD)	 for	 each	
receptor and thereby determine their β2/β1AR	 selectivity.	 The	
NanoBRET	binding	assay	has	been	successfully	 implemented	for	
ligand-	binding	 studies	 at	 the	 NLuc-	β1AR
34	 and	 NLuc-	β2AR
29,41 
using	propranolol-	based	 fluorescent	 probes.	An	 established	 sta-
ble	HEK293	T	cell	line	expressing	the	NLuc-	β2AR	was	used	for	the	
evaluation of ligand- binding properties at the β2AR,	whereas	β1AR	
affinities	 were	 determined	 in	 HEK293	 T	 cells	 transiently	 trans-
fected	to	express	NLuc-	β1AR.
All	 nine	 fluorescent	 ligands	 displayed	 saturable	 binding	 at	 the	
NLuc-	β2AR	(Figure	2;	Table	1).	Minimal	non-	specific	binding	was	ob-
served following co- incubation with 10 μM	propranolol.	The	majority	
of the fluorescent ligands displayed minimal specific binding at the 
NLuc-	β1AR	 up	 to	 the	 highest	 concentration	 used	 (500	 nM)	 in	 this	
assay	 (Figure	2;	Table	1).	Only	one	compound	 (9a)	 displayed	 signif-
icant specific binding (p<0.05;	 two-	way	ANOVA)	 to	 the	NLuc-	β1AR	
over this concentration range (pKD	6.65	±	0.15,	n	=	6;	Figure	2F).	The	
estimated affinity for 9a	at	the	NLuc-	β1AR	was,	however,	an	order	of	
magnitude	lower	than	that	measured	at	the	NLuc-	β2AR	(pKD 7.57 ± 
0.06,	n	=	5;	Table	1).
Two fluorescent ligands with different spectral prop-
erties were selected for further characterization. 9c (ICI 
118,551-	Gly-	Ala-	BODIPY-	FL-	X;	 green	 ligand)	 and	 12a (ICI 
118,551-	PEG-	BODIPY-	630/650-	X;	 red	 ligand)	 were	 selected	 due	
to their β2AR/β1AR	selectivity,	affinity	at	the	NLuc-	β2AR,	and	their	
different	fluorophores,	respectively.	The	specific	binding	of	both	li-
gands was inhibited by a panel of βAR	ligands	(Figure	3).	The	result-
ing	affinities	of	 these	unlabeled	 ligands	at	 the	NLuc-	β2AR	were	 in	
good agreement with literature values previously determined with 
radioligand binding at the untagged β2AR	(Table	2).
36,44
In	order	to	check	that	the	NLuc	tag	did	not	influence	ligand	bind-
ing to each βAR	 subtype,	 we	 performed	 competition	 radioligand	
binding	studies	 in	CHO	cells	 stably	expressing	 the	wild-	type	β1AR	
or β2AR	subtype.	CHO	cells	were	chosen	since	they	do	not	endog-
enously	express	βARs.	β2AR/β1AR	selectivity	was	maintained	with	
9c and 12a displaying comparable affinities to those seen in the 
NanoBRET	assays	(Table	3;	Figure	S2).
3.3  |  Confocal imaging of β2AR in transfected 
HEK293 T cells
To	assess	the	imaging	properties	of	two	ICI	118,551	derivatives	
containing	the	green	BODIPY-	FL-	X	fluorophore	(9c, 8c) and two 
containing	 the	 red	 BODIPY-	X-	630/650	 fluorophore	 (9a, 9c),	
confocal	microscopy	was	 carried	 out	 on	 an	HEK293	 T	 cell	 line	
stably	 expressing	 the	 SNAP-	β2AR.	 The	 cells	 were	 labeled	 with	
SNAP	 surface	 Alexa	 Fluor	 647	 or	 488,	 depending	 on	 the	 fluo-
rescent	 ligand	under	 investigation.	Equatorial	 plane	 images	 fol-
lowing 30- minute pre- incubation of the cells with fluorescent 
ligand	(100	nM)	at	37ºC	displayed	clear	membrane	localization	of	
the	ligand	which	matched	that	observed	with	the	SNAP-	labeled	
receptor	 (Figure	 4).	 Some	 SNAP-	labeled	 receptor	 was	 also	 ob-
served within the cytosol of cells indicating the presence of in-
ternalized	 receptor.	 The	 SNAP	 label	 is	 cell-	impermeant	 and	 as	
such any label internal to the cell must have been actively inter-
nalized alongside the receptor.
All	four	fluorescent	ICI	118,551	derivatives	were	detected	
to	 differing	 extents	 inside	 cells	matching	 the	 distribution	 of	
β2ARs	 seen	with	 the	 SNAP	 dye.	 This	 suggested	 that	 the	 flu-
orescent ligand had either been internalized along with re-
ceptor or is able to cross the cell membrane independently 
and then bind to intracellular receptors. The presence of in-
ternalized	SNAP-	β2AR	associated	with	fluorescent	ligand	was	
most apparent with 12a	 (Figure	 4G),	 which	 suggests	 that	 a	
combination	 of	 the	 PEG	 linker	 and	 the	 BODIPY-	X-	630/650	
makes	 this	 ICI	 118,551	 derivative	 particularly	 susceptible	 to	
crossing the cell membrane to the intracellular regions of the 
cell	(Figure	4G).
No	wash	steps	were	performed	 in	these	experiments,	but	free	
fluorescent ligand was not detected within the imaging buffer. This 
is	a	property	common	to	 the	BODIPY	fluorophores,	which	appear	
to	have	a	greater	quantum	yield	when	bound	to	GPCRs	in	a	lipid	en-
vironment.45 To establish the specific binding of 8c, 9a,	9c, and 12a 
F I G U R E  1 Structures	of	fluorescent	ICI	
118,551	derivatives
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to	 the	SNAP-	β2AR,	cells	were	pre-	incubated	with	10	μM	propran-
olol	 for	30	minutes	prior	 to	addition	of	 fluorescent	 ligand.	A	clear	
reduction in membrane fluorescence of all four fluorescent ligands 
was	observed,	indicating	that	the	majority	of	fluorescence	denotes	
specific	 binding	 to	 the	SNAP-	β2AR	 (Figure	4;	 Figure	S3).	 This	was	
also true of the cytosolic receptor binding.




was used to test for differences between total and non- specific binding for each fluorescent ligand. Significant differences (P	<	.05)	were	
obtained	for	the	data	in	A,	B,	C,	and	F
No
Fluorescent ICI 118,551 
analog β2AR pKD n β1AR pKD n
8a ICI	118,551-	Gly-	Ala-	
BODIPY-	X−630/650
7.48	±	0.08 6 NSB 5
8b ICI	118,551-	Gly-	Ala-	
BODIPY-	FL
6.31 ± 0.11 4 NSB 5
8c ICI	118,551-	Gly-	Ala-	
BODIPY-	FL-	X
7.48	±	0.10 6 NSB 5
9a ICI	118,551-	βAla-	βAla-	
BODIPY-	X−630/650
7.57 ± 0.06 5 6.69 ± 0.15 6
9b ICI	118,551-	βAla-	βAla-	
BODIPY-	FL
7.07 ± 0.10 5 NSB 5
9c ICI	118,551-	βAla-	βAla-	
BODIPY-	FL-	X
7.48	±	0.08 5 NSB 5
12a ICI	118,551-	PEG-	
BODIPY-	X−630/650
7.56	±	0.08 5 NSB 5
12b ICI	118,551-	PEG-	BODIPY-	FL 7.42	±	0.18 4 NSB 5
12c ICI	118,551-	PEG-	BODIPY-	
FL-	X
7.25 ± 0.04 5 NSB 5




binding curves. Data are mean pKD ± 
S.E.M	for	n	separate	experiments.	NSB;	
no specific binding detected at the highest 
concentration of fluorescent ligand used 
(500	nM)
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3.4  |  NanoBRET imaging of the binding of 9a, 
9c, and 12a to transfected HEK293 T cells expressing 
recombinant NLuc- β2ARs
To	 evaluate	 whether	 the	 proximity	 requirements	 (<10	 nm)	 of	
NanoBRET	 allowed	 good	 localization	 of	 fluorescent	 ICI	 118,551	
analog	 binding	 to	 both	 cell	 surface	 NLuc-	β2ARs	 and	 intracellular	
NLuc-	β2ARs	in	transfected	HEK293	T	cells,	we	also	undertook	biolu-
minescence	imaging	using	an	Olympus	LV200	microscope	(Figure	5).	
Filtered	 luminescence	 from	 NLuc-	β2ARs	 was	 captured	 using	 a	
428/24	band-	pass	filter	to	allow	blue	light	largely	emitted	from	the	
N-	terminal	nanoluciferase	to	be	monitored.	BRET-	emitted	light	from	
the	red	BODIPY-	X-	630/650	fluorophore	attached	to	9a and 12a was 
captured	using	650/50	nm	band-	pass	 filter	 and	 the	BRET-	emitted	
light	from	the	green	BODIPY-	X-	FL	fluorophore	attached	to	9c was 




pranolol appeared higher for the green ligand (9c;	Figure	5l),	but	this	
is partly due to the bleed- through of nanoluciferase luminescence 
into the green channel.
3.5  |  Luminescence imaging NLuc- β2ARs in 
CRISPR/Cas9 genome- edited HEK293 T cells under 
endogenous promotion
In	 HEK293	 T	 cells,	 the	 endogenous	 expression	 of	 β2- 
adrenoceptors	 is	extremely	 low,	and	we	have	previously	shown	
that β2ARs	tagged	with	an	N-	terminal	SNAP	label	under	endog-
enous promotion are not detectable by standard confocal mi-
croscopy	in	CRISPR/Cas9	genome-	edited	HEK293	T	cells	(Figure	
S4).35	To	confirm	this	low	level	of	expression,	we	used	CRISPR/
Cas9	genome	editing	 to	 incorporate	 an	N-	terminal	NLuc	 tag	 to	
the β2AR	under	endogenous	promotion	as	we	have	described	pre-
viously.32	Quantification	of	NLuc-	β2AR	expression,	as	measured	





nal to noise ratio is much greater for bioluminescence imaging 
compared to standard confocal imaging and as such imaging at 











9c n 12a n
Propranolol 9.48	±	0.35 5 9.55 ± 0.32 6
ICI	118,551 8.95	±	0.26 6 8.98	±	0.21 6
CGP	20712A 6.03 ± 0.16 5 6.19 ± 0.27 6
Salmeterol 8.45	±	0.31 6 9.01 ± 0.36 5
TA B L E  3 Dissociation	constants,	pKi,	determined	from	inhibition	







β2AR n β1AR n
9c 8.29	±	0.17 5 ND 6
12a 7.64 ± 0.21 5 ND 6
ICI	118,551 8.76	±	0.22 5 6.44 ± 0.14 6
CGP	20712A ND 5 8.37	±	0.18 6
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endogenous	levels	is	possible.	It	must	be	noted,	however,	that	a	
longer	exposure	time	(1	min)	was	required	to	image	the	CRISPR/
Cas9	genome-	edited	NLuc-	β2AR	 than	 the	 transfected	cell	 lines	
(5	sec,	Figure	6B-	E).
3.6  |  NanoBRET binding of 9c and 12a to CRISPR/
Cas9 genome- edited NLuc- β2ARs under endogenous 
promotion in HEK293 T cells
The	 huge	 dynamic	 range	 (brightness)	 of	 the	 nanoluciferase	 lumi-
nescence	allowed	NanoBRET	ligand	binding	of	both	9c and 12a to 
be	monitored	in	genome-	edited	HEK293	T	cells.	The	PEG-	BODIPY-	
X-	630/650	 analog	 of	 ICI	 118,551	 (12a)	 showed	 clear	 saturable	
binding with a pKD	value	of	7.84	±	0.17	(n	=	7;	Figure	7A),	which	was	
similar	to	the	7.56	±	0.08	(n	=	5)	determined	for	12a in the trans-
genic	cell	line	(Table	1).	The	level	of	non-	specific	binding	(obtained	




(9.70 ± 0.22; n	=	5)	showing	high	affinity	and	the	β1- selective an-
tagonist	CGP	20712A	a	very	low	affinity	(Figure	7B).	Similarly,	the	
βAla-	βAla-	BODIPY-	FL-	X	 analog	 of	 ICI	 118,551	 (9c)	 also	 showed	
clear	saturable	binding	to	NLuc-	β2ARs	in	genome-	edited	HEK293	T	
cells	(Figure	8A)	with	a	pKD 7.71 ± 0.14 (n	=	6)	that	was	similar	to	
that	measured	in	transgenic	HEK293	T	cells	(7.48	±	0.08;	Table	1),	
although the level of non- specific binding appeared higher than 
observed	with	the	red	ligand	(Figure	8A).	This	is	likely	to	be	due	to	
bleed- through of nanoluciferase luminescence into the green chan-
nel	(509/22	nm).	Competition	binding	experiments	in	this	cell	line	
with 9c	also	showed	the	expected	β2- selectivity with propranolol 
(pKi 9.55 ± 0.22; n	=	7)	and	salmeterol	(pKi	8.98	±	0.27;	n	=	6),	and	
ICI	118,551	 (9.69	±	0.22;	n	=	7)	showing	high	affinity	and	the	β1- 
selective	 antagonist	 CGP	 20712A	 a	 much	 lower	 affinity	 (6.46	 ±	
0.12; n	=	4;	Figure	8B).
Finally,	 we	 investigated	 whether	 NanoBRET	 ligand	 binding	
could	 be	 visualized	 in	 CRISPR/Cas9	 genome-	edited	 cells	 using	
luminescence microscopy. Clear specific binding was detectable 














to insert both luminescent and fluorescent tags onto the N- terminus 
of	GPCRs	 into	 the	 endogenous	 genome,	where	 their	 expression	 is	






incubation in the presence or absence 
of 10 μM	propranolol.	Fluorescent	
localization of the β2AR	(C,	G,	K,	O)	
matches	that	illustrated	by	the	SNAP-	
tagged	dye	(A,	E,	I,	M)	and	is	prevented	
from binding after propranolol addition 
(D,	H,	L,	P).	Similar	data	were	obtained	in	
three	further	experiments
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regulated by endogenous promoters.30-	32,35 In the present manu-
script,	 we	 have	 investigated	 the	 utility	 of	 highly	 selective	 fluores-
cent ligands based on the β2AR	selective	antagonist	ICI	118,551
33 in 
combination	with	CRISPR/Cas9	genome	editing	to	investigate	ligand	





The highly β2AR-	selective	 antagonist	 ICI	 118,551	 was	 used	
as the starting point for the development of selective β2AR	 flu-
orescent ligands. We generated a small focused library of nine 
ligands based on combinations of different linkers and fluoro-
phores.	 With	 the	 exception	 of	 ICI	 118,551-	Gly-	Ala-	BODIPY-	FL,	
the	 remaining	 fluorescent	 ICI	 118,551	 analogs	 had	 good	 affin-
ity (pKD	 >7)	 for	 the	 β2AR	 with	 good	 selectivity	 over	 the	 β1AR	
(Table	1)	with	the	most	potent	and	selective	ligands	being	8c (ICI 
118,551-	Gly-	Ala-	BODIPY-	FL-	X),	9c	(ICI	118,551	βla- βAla-	BODIPY-	
FL-	X),	 12a	 (ICI	 118,551-	PEG-	BODIPY-	X-	630/650),	 and	 12b (ICI 
118,551-	PEG-	BODIPY-	FL).
9a	 (ICI	118,551-	βAla-	βAla-	BODIPY-	X-	630/650)	had	the	highest	
affinity at recombinant β2ARs	(pKD	7.57)	but	also	exhibited	signifi-
cant binding affinity for the β1AR	(pKD	6.69).	Nevertheless,	among	
the	red	fluorescent	ligands,	9a had the best imaging characteristics 
(in	terms	of	signal	to	noise	and	the	extent	of	non-	specific	binding)	
in	 recombinant	HEK293	 T	 cells	 and	 labeling	was	mostly	 confined	
to	 the	cell	 surface	 (Figure	4).	 In	contrast,	12a showed the highest 
propensity to label intracellular β2ARs	in	HEK293	T	cell	expressing	
exogenous	 receptor.	 This	 suggests	 that	 a	 combination	of	 the	PEG	
linker	and	the	BODIPY-	X-	630/650	makes	this	ICI	118,551	derivative	
particularly susceptible to crossing the cell membrane to access the 




pendent on β- arrestin recruitment to the receptor.48 It is also known 
that β2ARs	 can	 continue	 to	 signal	 from	 intracellular	 endosomes
49 
and	so	fluorescent	ligands,	such	as	12a, which appear to be cell per-
meable and can access endosomal β2ARs,	may	have	utility	in	unrav-
eling	the	complexities	of	signaling	from	intracellular	β2ARs.





significantly reduced in the presence of propranolol; paired t- test *P	<	.05.	Grouped	average	±S.E.M.	is	displayed.	Scale	bar	represents	50	μm
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The	much	lower	expression	of	β2ARs	in	native	HEK293	T	cells	was	
confirmed	when	the	luminescence	detected	from	NLuc	was	compared	




















constant. Comparative luminescence is 
illustrated	by	line	profiles	(50	µm)	for	(C)	
endogenous	and	(E)	exogenous	captures.	
Scale bar represents 50 µm
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approach	with	CXCR4	chemokine	receptors.31	Nevertheless,	even	at	
this	low	expression	level	in	the	CRISPR	genome-	edited	cells,	we	were	
able	 to	visualize	 the	expression	of	NLuc-	β2ARs	using	 real-	time	 lumi-
nescence microscopy in a manner which was not possible using con-
ventional confocal microscopy of a similar genome- editing approach 
to	insert	a	SNAP-	based	fluorescent	tag	onto	the	native	β2ARs.
35 This 
shows the huge advantage of using the very bright nanoluciferase and 
the ability to capitalize on its large dynamic range50	to	visualize	NLuc-	
tagged	receptors	at	very	low	expression	levels.
The combination of highly β2AR-	selective	fluorescent	ligands	and	
genome-	edited	 cells	 expressing	 NLuc-	β2ARs	 under	 the	 control	 of	
their	native	promoters	has	enabled	real-	time	NanoBRET	ligand	bind-
ing to be performed on these receptors for the first time. The high 
β2AR-	selectivity	removes	any	complications	caused	by	the	potential	
of the fluorescent ligand binding to endogenous β1ARs	and	mediating	
a	BRET	signal	via	bystander	resonance	energy	transfer.	Furthermore,	
the ligand- binding properties in terms of competition by selective β2- 
and β1-	ligands	in	CRISPR/Cas9-	edited	cells	were	very	similar	to	those	
obtained for the transgenic cell line. The pKD values obtained for both 
12a	 (ICI	118,551-	PEG-	BODIPY-	X-	630/650)	and	the	green	 ligand	9c 
(ICI	118,551	βAla-	βAla-	BODIPY-	FL-	X)	were	similar	to	the	values	ob-
tained with the same fluorescent ligand in the transfected cell line.









of propranolol; paired t- test *P	<	.05.	Paired	experiments	are	connected	by	line.	Scale	bar	represents	50	µm
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5  |  CONCLUSION
In	 summary,	 the	 present	 manuscript	 has	 generated	 some	 high	
β2AR-	selective	fluorescent	ligands	based	on	ICI	118	,551	that	have	
been used to investigate ligand binding to β2ARs	in	CRISPR/Cas9	
genome-	edited	HEK293	T	cells	where	 the	endogenous	 receptor	
expression	 is	extremely	 low.	We	have	used	 these	 ligands	 to	un-
dertake for the first time real- time ligand binding to the native 
β2ARs	 to	provide	both	quantitative	data	on	 ligand-	binding	 char-
acteristics and to allow visualization of the ligand- binding inter-
actions	using	NanoBRET	 luminescence	 imaging.	The	 fluorescent	
ligands studied have different abilities to label intracellular β2ARs	
and	these	should	be	valuable	tools	to	help	unravel	the	complexi-
ties of β2AR	 pharmacology	 in	 endosomal	 compartments	 where	
these receptors can continue to signal after agonist- induced re-
ceptor endocytosis.
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